UCB to acquire Ra Pharmaceuticals in $2bn deal

14-10-2019

Saman Javed

UCB to acquire Ra Pharmaceuticals in $2bn deal

brauns / iStockphoto.com

Belgium head-quartered pharmaceutical company UCB is to acquire Ra Pharmaceuticals for approximately $2.1 billion.


UCB, Ra Pharmaceuticals, immune system, immunology, disease, merger, acquisition

More on this story

Teva infringed UCB patent, rules Fed Circuit
25-06-2019

LSIPR